Subsequently, second-generation CARs containing an additional co-stimulatory signaling molecule, such as 4-1BB, CD28, CD27, OX40 or ICOS have been developed to stimulate an endogenous immune response against tumor cells via epitope spreading 20. Here, ICOS is linked to neoplasm.